We are live on ! Find out more
ALT icon

Altimmune

88 hedge funds and large institutions have $231M invested in Altimmune in 2020 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 27 increasing their positions, 16 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

76% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 21

69% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 16

22% more funds holding

Funds holding: 7288 (+16)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

4.73% less ownership

Funds ownership: 66.54%61.81% (-4.7%)

19% less capital invested

Capital invested by funds: $285M → $231M (-$54.8M)

22% less call options, than puts

Call options by funds: $5.2M | Put options by funds: $6.7M

Holders
88
Holders Change
+16
Holders Change %
+22.22%
% of All Funds
1.56%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
37
Increased
27
Reduced
16
Closed
21
Calls
$5.2M
Puts
$6.7M
Net Calls
-$1.5M
Net Calls Change
-$2.58M
Name Holding Trade Value Shares
Change
Change in
Stake
Arrowstreet Capital
101
Arrowstreet Capital
Massachusetts
-$198K -15,000 Closed
SM
102
Sabby Management
Florida
-$182K -13,800 Closed
CH
103
CVI Holdings
Delaware
-$140K -10,600 Closed
FIA
104
FNY Investment Advisers
New York
-$85K -6,500 Closed
GWM
105
Geneos Wealth Management
Colorado
-$12K -1,000 Closed
Royal Bank of Canada
106
Royal Bank of Canada
Ontario, Canada
-$1K -113 Closed
Fidelity Investments
107
Fidelity Investments
Massachusetts
+$12 +1 New
JP Morgan Chase
108
JP Morgan Chase
New York
+$141 +12 New

ALT Hedge Fund Activity: Q4 2020 in Review

88 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q4 2020, worth a combined $231M — down 19% from $285M a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new ALT positions and 21 closed out — a net gain of 16 holders — while 27 added to existing stakes and 16 trimmed.

The largest buyer was UBS Group, adding an estimated $16.5M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $26.4M sold.

  • 88 institutional investors held Altimmune (ALT) as of Q4 2020, up from 72 in Q3 2020.
  • Funds reported $231M of Altimmune stock for Q4 2020, down 19% quarter-over-quarter.
  • 37 funds opened new Altimmune positions in Q4 2020 and 21 closed out, a net change of +16 holders.
  • The largest Altimmune buyer in Q4 2020 was UBS Group, an estimated $16.5M added.
  • The largest Altimmune seller in Q4 2020 was Avoro Capital Advisors, an estimated $26.4M sold.

Based on aggregated 13F filings for Q4 2020.